The expansion adds 100 m³ of reactor capacity, significantly strengthening Siegfried’s position among the world’s leading CDMOs for small-molecule drug substances
The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank
Keeps Halo Pharma to drive independent growth
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
